Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Diabetes mellitus risk in rheumatoid arthritis: Reduced incidence with anti–tumor necrosis factor α therapy

Diabetes mellitus risk in rheumatoid arthritis: Reduced incidence with anti–tumor necrosis factor... Objective To examine the association of tumor necrosis factor α (TNFα) inhibitor use and the risk of developing diabetes mellitus in a rheumatoid arthritis (RA) inception cohort. Methods Adults diagnosed with RA between January 1, 2001, and December 31, 2009, were identified (n = 1,881). Prevalent cases of diabetes mellitus (n = 294) were excluded. Information on sociodemographic data, medical history, body mass index (BMI), laboratory measures, and medications was collected from the electronic health record. Incident diabetes mellitus was defined using the 2010 American Diabetes Association criteria or physician‐established diagnosis. Time‐varying Cox proportional hazards regression models were used to adjust for age, sex, race, BMI, rheumatoid factor (RF) and anti–cyclic citrullinated peptide antibodies (anti‐CCP), erythrocyte sedimentation rate (ESR), and use of nonsteroidal antiinflammatory drugs (NSAIDs), glucocorticoids, hydroxychloroquine, and methotrexate. Results A total of 1,587 incident RA patients without diabetes mellitus were included. The anti‐TNFα users (n = 522) had a lower median age but greater baseline BMI; maximum ESR, RF, and anti‐CCP positivity; and NSAID, glucocorticoid, or methotrexate use. The median followup time for the ever and never TNFα inhibitor users was 44.9 months (interquartile range (IQR) 23.7–73.0 months) and 37.1 months (IQR 16.3–65.1 months), respectively (P < 0.001). Of the 91 patients developing diabetes mellitus, 16 were ever and 75 were never TNFα inhibitor users, yielding incidence rates of 8.6 and 17.2 per 1,000 person‐years (P = 0.048), respectively. Adjusting for covariates, the hazard ratio for incident diabetes mellitus in TNFα inhibitor users was 0.49 (95% confidence interval 0.24–0.99, P = 0.049) compared to the never users. Conclusion In this inception RA cohort, anti‐TNFα use was associated with a 51% reduction in risk of developing diabetes mellitus. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Arthritis Care & Research Wiley

Diabetes mellitus risk in rheumatoid arthritis: Reduced incidence with anti–tumor necrosis factor α therapy

Download PDF
7 pages

Loading next page...
 
/lp/wiley/diabetes-mellitus-risk-in-rheumatoid-arthritis-reduced-incidence-with-bYWPcR9loO

References (44)

Publisher
Wiley
Copyright
Copyright © 2012 by the American College of Rheumatology
ISSN
2151-464X
eISSN
2151-4658
DOI
10.1002/acr.20657
pmid
21972198
Publisher site
See Article on Publisher Site

Abstract

Objective To examine the association of tumor necrosis factor α (TNFα) inhibitor use and the risk of developing diabetes mellitus in a rheumatoid arthritis (RA) inception cohort. Methods Adults diagnosed with RA between January 1, 2001, and December 31, 2009, were identified (n = 1,881). Prevalent cases of diabetes mellitus (n = 294) were excluded. Information on sociodemographic data, medical history, body mass index (BMI), laboratory measures, and medications was collected from the electronic health record. Incident diabetes mellitus was defined using the 2010 American Diabetes Association criteria or physician‐established diagnosis. Time‐varying Cox proportional hazards regression models were used to adjust for age, sex, race, BMI, rheumatoid factor (RF) and anti–cyclic citrullinated peptide antibodies (anti‐CCP), erythrocyte sedimentation rate (ESR), and use of nonsteroidal antiinflammatory drugs (NSAIDs), glucocorticoids, hydroxychloroquine, and methotrexate. Results A total of 1,587 incident RA patients without diabetes mellitus were included. The anti‐TNFα users (n = 522) had a lower median age but greater baseline BMI; maximum ESR, RF, and anti‐CCP positivity; and NSAID, glucocorticoid, or methotrexate use. The median followup time for the ever and never TNFα inhibitor users was 44.9 months (interquartile range (IQR) 23.7–73.0 months) and 37.1 months (IQR 16.3–65.1 months), respectively (P < 0.001). Of the 91 patients developing diabetes mellitus, 16 were ever and 75 were never TNFα inhibitor users, yielding incidence rates of 8.6 and 17.2 per 1,000 person‐years (P = 0.048), respectively. Adjusting for covariates, the hazard ratio for incident diabetes mellitus in TNFα inhibitor users was 0.49 (95% confidence interval 0.24–0.99, P = 0.049) compared to the never users. Conclusion In this inception RA cohort, anti‐TNFα use was associated with a 51% reduction in risk of developing diabetes mellitus.

Journal

Arthritis Care & Research – Wiley

Published: Feb 1, 2012

There are no references for this article.